Journal
MOLECULAR INTERVENTIONS
Volume 10, Issue 5, Pages 271-281Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mi.10.5.4
Keywords
-
Categories
Funding
- National Institutes of Health [R01EY14428, RO1EY18660]
- Research to Prevent Blindness
- Ruth and Milton Steinbach Fund
- Ronald McDonald House Charities
- Macular Vision Research Foundation
- Burroughs Wellcome Fund Clinical Scientist Award in Translational Research
- West China Hospital of Sichuan University
- NATIONAL EYE INSTITUTE [R01EY018660, R01EY014428] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Age-related macular degeneration (AMD) is the most common cause of visual impairment among the elderly in developed countries, and its prevalence is thus increasing as the population ages; however, treatment options remain limited because the etiology and pathogenesis of AMD are incompletely defined. Recently, much progress has been made in gene discovery and mechanistic which clearly indicate that AMD involves the interaction of multiple genetic and environmental factors. The identification of genes that have a substantial impact on the risk for AMD is not only facilitating the diagnosis and screening of populations at risk but is also elucidating key molecular pathways of pathogenesis. Pharmacogenetic studies of treatment responsiveness among patients with the wet form of AMD are increasingly proving to be clinically relevant; pharmacogenetic approaches hold great promise for both identifying patients with the best chance for vision recovery as well as tailoring individualized therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available